KD DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Kyndryl (KD) Investors of Securities Class Action Deadline on April 13, 2026 Ready to Announce with Confidence?

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Kyndryl To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Kyndryl between August 7, 2024 and February 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - March 8, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kyndryl Holdings, Inc. ("Kyndryl" or the "Company") (NYSE: KD) and reminds investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) manufacturing for Inovio's CELLECTRA device was deficient; (2) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were overstated; and (5) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On December 29, 2025, the U.S. Food and Drug Administration ("FDA") announced it had accepted Inovio's Biologics License Application ("BLA") for INO-3107, a treatment for recurrent respiratory papillomatosis, on a standard review timeline. Inovio filed its BLA under the accelerated approval pathway, but the FDA stated that the Company did not submit adequate information to justify eligibility for accelerated approval. Inovio also announced it does not currently plan to seek approval under the standard review timeline, and will request a meeting with the FDA to discuss how it may still pursue accelerated approval.

On this news, Inovio's stock price fell $0.56 per share, or 24.45%, to close at $1.73 per share on December 29, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Kyndryl's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Kyndryl class action, go to www.faruqilaw.com/KD or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286549

Source: Faruqi & Faruqi LLP

Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Faruqi & Faruqi LLP or all companies in the Banking / Financial Services industry.

KD DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Kyndryl (KD) Investors of Securities Class Action Deadline on April 13, 2026

2026-03-08 8:49 AM EDT

VTGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Vistagen (VTGN) Investors of Securities Class Action Deadline on March 16, 2026

2026-03-08 8:49 AM EDT

INO DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026

2026-03-08 8:47 AM EDT

Dec 16, 2025

What makes a press release rise above the rest? We analyzed the most successful press releases of 2025 to see what caught attention and why. This year’s review looks at total views from human readers and AI systems across the top five hundred public company press releases distributed through TMX Newsfile in 2025. These views come from all of Newsfile’s general distribution channels, such as Yahoo and Apple. They reflect how audiences discovered and engaged with each announcement. Key Insights...

Litigation and Regulation

Banking / Financial Services